Navigating the challenges of managing acute kidney injury in sickle cell anaemic adolescent boy in a resource poor setting- a case report
Article Sidebar
Main Article Content
Abstract
Managing Acute Kidney Injury (AKI) in a patient with Sickle Cell Anaemia (SCA) can be challenging, particularly when the patient is haemodynamically unstable and peritoneal dialysis is not feasible. We report the case of a 17-year-old male with Homozygous SCA (HbSS), diagnosed at age 2years, who presented with AKI and hypertensive emergency following Graham’s patch repair for a perforated duodenal ulcer, likely due to chronic NSAID use.
By postoperative day 5, he developed facial and pedal oedema, oliguria, elevated blood pressure (up to 190/140 mmHg), and a rise in serum creatinine (644.4 µmol/L), urea (26.7 mmol/L), and potassium (6.25 mmol/L). A diagnosis of AKI on a background of sickle cell nephropathy was made.
Given the haemodynamic concerns, haemodialysis was initiated cautiously. Measures taken included: (1) priming of dialysis machine and bloodlines with freshly donated genotype-AA blood, (2) intra-dialysis transfusion, (3) limiting the first dialysis session to 2 hours, and (4) ultrafiltration volume based on pre-AKI and current weight.
The patient tolerated three sessions of haemodialysis on alternate days. He experienced remarkable clinical improvement, with a stable blood pressure of 125/70 mmHg, a reduced serum creatinine level of 163.7 µmol/L, and an improved urine output of 3.1 mL/kg/hr. He was discharged on antihypertensives and scheduled for outpatient follow-up.
This case highlights the feasibility and safety of carefully monitored haemodialysis in haemodynamically unstable SCA patients with AKI, even in resource-limited settings.
Article Details
Copyright (c) 2025 Ajite A, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease. 2000-2021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. Available from: https://doi.org/10.1016/s2352-3026(23)00118-7
2. Centres for Disease Control and Prevention, Global Health Reports. Nigeria, Centres for Disease Control and Prevention. 2012.
3. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-487. Available from: https://doi.org/10.2471/blt.06.036673
4. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11(3):161-71. Available from: https://doi.org/10.1038/nrneph.2015.8
5. Hariri E, Mansour A, El Alam A, et al. Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol. 2018;50:1075–1083. Available from: https://doi.org/10.1007/s11255-018-1803-3
6. Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.researchgate.net/publication/342546954_Sickle_Cell_Nephropathy
7. Han J, Saraf SL, Lash JP, Gordeuk VR. Use of anti-inflammatory analgesics in sickle cell disease. J Clin Pharm Ther. 2017;42(5):656-660. Available from: https://doi.org/10.1111/jcpt.12592
8. Dunn MJ, Zambraski EJ. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int. 1980;10(5):609-622. Available from: https://doi.org/10.1038/ki.1980.179
9. Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of non-steroidal anti-inflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum. 1985;14:163-175. Available from: https://doi.org/10.1016/0049-0172(85)90035-6
10. Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59(2):386-390. Available from: https://doi.org/10.1002/pbc.24175
11. Sharpe CC, Thein SL. How I treat renal complications in sickle cell disease. Blood. 2016;123(24):3720–7. Available from: https://doi.org/10.1182/blood-2014-02-557439
12. Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. Am J Hematol. 2014;89(9):907–14. Available from: https://doi.org/10.1002/ajh.23762
13. Zar R, Chen S, Hankins JS, Wang WC. The natural history of glomerular hyperfiltration in sickle cell disease. Blood. 2024;144(Suppl 1):3886. Available from: http://dx.doi.org/10.1182/blood-2024-199586
14. Boyle SM, Jacobs B, Sayani FA, Hoffman B. Management of the dialysis patient with sickle cell disease. Semin Dial. 2016;29(1):62-70. Available from: https://doi.org/10.1111/sdi.12403
15. Nath J, McDaid J, Bentall A, Ball S, Ready AR, Inston NG. Sickle cell and renal transplant: a national survey and literature review. Exp Clin Transplant. 2012;10(1):1-7. Available from: https://doi.org/10.6002/ect.2011.0098
16. Okafor UH, Aneke E. Outcome and challenges of kidney transplant in patients with sickle cell disease. J Transplant. 2013;2013:614610. Available from: https://doi.org/10.1155/2013/614610
17. Adzika VA, Glozah FN, Ayim-aboagye D, Ahorlu CSK. Socio-demographic characteristics and psychosocial consequences of sickle cell disease: the case of patients in a public hospital in Ghana. J Health Popul Nutr. 2017;36:1–10. Available from: https://pure.ug.edu.gh/en/publications/socio-demographic-characteristics-and-psychosocial-consequences-o-3
18. Adegoke SA, Kuteyi EA, Health C, Awolowo O, Adegoke S. Psychosocial burden of sickle cell disease on the family, Nigeria. 2012;6–11.
19. Olowu WA. Renal failure in Nigerian children: factors limiting dialysis access. Pediatr Nephrol. 2003;18(12):1249-54. Available from: https://doi.org/10.1007/s00467-003-1255-5